#United States #Palo Alto #pancreatic cancer #Sonire Therapeutics #HIFU therapy

Sonire Therapeutics Receives $18 Million Series A Funding

Sonire Therapeutics, a cutting-edge clinical-stage medical device company based in the U.S., has announced the successful closure of an $18 million Series A financing round. This significant funding, led by Santé Ventures, aims to propel the company’s innovative High-Intensity Focused Ultrasound (HIFU) therapy designed specifically for pancreatic cancer treatment. This groundbreaking therapy represents a potential shift in how non-invasive cancer treatments are approached.

The Financial Backing

The financing round witnessed participation from notable investors, including Fast Track Initiative (FTI), Japan's Nomura SPARX Investment, and SBI Investment among others. The infusion of capital is earmarked for several strategic initiatives, including the completion of what is expected to be the first randomized controlled trial of HIFU therapy on pancreatic cancer patients, as well as to bolster the company's regulatory processes in the U.S., following its receipt of FDA Breakthrough Device Designation in 2024.

Innovative Medical Device

Sonire’s proprietary HIFU therapy system stands out due to its combination of state-of-the-art real-time imaging guidance and patented technological advancements, including a comprehensive noise-cancellation system and a unique robot-assisted positioning platform. This system allows for rapid and precise thermal ablation, distinguishing itself from conventional ultrasound-guided systems. Moreover, Sonire's solution mandates no anesthesia, creating a patient-friendly atmosphere where treatments can be completed in approximately twenty minutes on an outpatient basis. Such an approach not only eases the procedure for patients but also alleviates the staff and cost burdens traditionally associated with cancer care.

Aiming for Improved Patient Outcomes

Tohru Satoh, President and CEO of Sonire Therapeutics, expressed gratitude for the investor support, asserting that it reflects confidence in the transformative potential of their sonic technology. He emphasized that this financial boost will facilitate the completion of the SUNRISE-I trial in Japan, the world’s first randomized trial for HIFU therapy targeting pancreatic cancer, while simultaneously setting the stage for essential U.S. clinical developments.

Pancreatic cancer remains one of the deadliest malignancies globally, with an alarming five-year survival rate of merely 12%. Current treatment options are often limited, leaving a gaping need for innovative local therapy alternatives. Sonire's novel method intends not only to lengthen survival but also to provide patients with a safer, less invasive alternative to traditional surgery and radiation treatments, potentially improving their quality of life.

Clinical Insights

Recent studies, including foundational work from the MoonShot-2 trial utilizing a prototype HIFU system, have shown promising results. The study recorded a 66% disease control rate among patients suffering from advanced forms of pancreatic and biliary tract cancers when treated through sonodynamic therapy settings. These findings are pivotal, as they form the backbone of Sonire's current system development. The ongoing SUNRISE-I study compares the effects of HIFU combined with chemotherapy against chemotherapy alone, and is currently conducted across seven preeminent hospitals in Japan.

Moving Forward

Dennis McWilliams, Managing Director for Santé, remarked on Sonire's breakthrough HIFU technology, highlighting its ability to address previous challenges surrounding visualization and workflow that had hindered advancements in HIFU applications so far. The objective of this new treatment modality aims to provide substantial benefits to patients worldwide, and the investment will help expand Sonire’s operational footprint in the United States while building on its strong clinical foundation in Japan.

Sonire Therapeutics, established in February 2020 and currently headquartered in Palo Alto, California, is determined to revolutionize oncology by utilizing innovative, patient-centered approaches to cancer treatment. For more information on their groundbreaking work and upcoming trials, visit Sonire Therapeutics.